Nasdaq Welcomes Moderna, Inc. (Nasdaq: MRNA) to The Nasdaq Stock Market
NEW YORK, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on the Nasdaq Stock Market.
Moderna is a leader in the development of mRNA medicines, a new class of drugs that directs the body’s cells to produce proteins that have the potential to prevent, treat or cure disease. The company has a pipeline of 21 development candidates, including 10 programs currently in clinical trials. These programs span diverse areas such as cancer, infectious disease, cardiovascular disease and rare genetic disorders. Moderna has both solely controlled programs and strategic collaborations with leading pharmaceutical companies including AstraZeneca and Merck, global non-profit organizations and government agencies.
“We believe this milestone will further enable us to advance our pipeline of investigational mRNA medicines to improve the lives of people with serious diseases,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We set out to build a platform that would enable us to optimize the full potential of mRNA and develop novel vaccines and therapies. I am proud of our team and their relentless drive to expand the frontiers of mRNA science and create a potential new category of medicines for patients.”
“Moderna’s deep commitment to mRNA discovery, research and development, supported by its team of world-class scientists and researchers and its state-of the art technology platform and infrastructure, sets them apart as an industry leader within the biotechnology sector,” said Nelson Griggs, President, Nasdaq Stock Exchange. “We are excited to welcome Moderna to the Nasdaq Stock Exchange and look forward to supporting the company’s commitment to developing transformative medicines for patients around the world.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About NasdaqNasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 4,000 total listings with a market value of approximately $14 trillion. To learn more, visit: http://business.nasdaq.com
MEDIA RELATIONS CONTACT:
Emily Pan(646) 441-5120 email@example.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/63bc1237-3bf3-4ac4-99b0-6c07b738e939